Equine p-tau212 and 214 antibody and antigen (recombinant protein)
Diagnostic anti-Equine p-tau212 and 214 antibodies pairs and antigen for animal health (animal Equine/Horse Alzheimer Disease(AD)) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Equine disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-EQU-p-tau212-214-Ag01 | Equine p-tau212 and 214 | $3090.00 |
GMP-EQU-p-tau212-214-Ab01 | Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-p-tau212-214-Ab02 | Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-p-tau212-214-Ab03 | Anti-Equine p-tau212 and 214 human monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-p-tau212-214-Ab04 | Anti-Equine p-tau212 and 214 human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-EQU-p-tau212-214-Ag01 |
Product Name | Equine p-tau212 and 214 |
Target/Biomarker | Equine p-tau212 and 214 |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Equine p-tau212 and 214 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau212 and 214 level test of animal Equine/Horse with Alzheimer Disease(AD). |
Tag | His | Reconized/Reactive Specics | Equine p-tau212 and 214 |
Product description | Recombinant Equine p-tau212 and 214 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-p-tau212-214-Ab01,GMP-EQU-p-tau212-214-Ab02 |
Target/Biomarker | Equine p-tau212 and 214 |
Product Name | Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Equine p-tau212 and 214 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine p-tau212 and 214 antibodies in Equine p-tau212 and 214 level test of animal Equine/Horse with Alzheimer Disease(AD). |
Product description | Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine p-tau212 and 214 antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-p-tau212-214-Ab03,GMP-EQU-p-tau212-214-Ab04 |
Target/Biomarker | Equine p-tau212 and 214 |
Product Name | Anti-Equine p-tau212 and 214 human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Equine p-tau212 and 214 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine p-tau212 and 214 antibodies in Equine p-tau212 and 214 level test of animal Equine/Horse with Alzheimer Disease(AD). |
Product description | Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
Equine p-tau212 and p-tau214 represent a subset of tau proteins specific to the equine neurological landscape. These phosphorylated tau variants are intricately involved in maintaining the structural stability of microtubules within neurons. Under normal circumstances, tau proteins bind to microtubules and aid in their assembly, ensuring proper neuronal function, axonal transport, and synaptic communication.
However, the equilibrium in tau phosphorylation is delicate, and when disrupted, it can have far-reaching consequences. In equine neurodegenerative disorders, such as certain tauopathies, aberrant phosphorylation of tau proteins occurs. This post-translational modification leads to tau proteins adopting abnormal conformations, which renders them prone to aggregation. The aggregation of tau proteins culminates in the formation of neurofibrillary tangles, a pathological hallmark reminiscent of similar neurodegenerative diseases in humans, like Alzheimer's disease.
Equine p-tau212 and p-tau214, phosphorylated at specific sites within the tau protein sequence, are indicative of this pathological cascade. They serve as early indicators of tauopathy-related neurodegenerative processes in horses. The presence of elevated levels of these biomarkers suggests ongoing tau phosphorylation and the potential emergence of cognitive and neurological deficits in affected equines.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.